Revolutionizing Cancer Treatment with Cutting-Edge Therapeutics to Eradicate Cancer.
Inspired by scientific discoveries in the lab, we are translating our findings into innovative cancer therapeutics for patients.
Inducing Cancer Cell Death Through BAK Activation
We are developing an innovative cancer therapeutic that activates BAK, a proapoptotic effector, to induce cancer cell death. Our groundbreaking BAK activator selectively destroys cancer cells that express high levels of BAK, suppressing tumor growth while causing less harm to normal cells with little or no BAK expression.
CombYSelect Platform for efficient IgG Heterodimerization
The CombYSelect (Combinatorial Tyrosine (Y)/Serine (S) Selection) is a computational AI approach that designs near-optimal heterodimerization without affecting IgG stability or function. Its utility is clearly demonstrated by engineering both a bispecific antibody and a cytokine trap for further therapeutic applications.
Bispecific Antibody and Bispecific Antibody-Drug Conjugates
The CombYSelect platform can create various types of bispecific antibodies with long half-lives, improved functionality, and enhanced stability. Innovative payloads, such as the BAK activator, can also be attached to the engineered bispecific antibody to improve the accuracy of treatments and reduce side effects from off-target or off-tumor toxicities.
About Us
Welcome to 7 Primus Biosciences, a leading biotech company specializing in targeted cancer therapeutics. We are developing a first-in-class, small molecule BAK activator that selectively destroys cancer cells. Our in vivo studies demonstrate its remarkable ability to suppress tumor growth while minimizing harm to normal tissues. Using the CombYSelect platform, we are developing the next generation of bispecific antibodies to enhance treatment specificity and sustainability.
Additionally, we are creating bispecific antibody-drug conjugates that combine the enhanced specificity of tumor-associated antigens through bispecific antibodies with the anti-tumor potency of the unique payload, such as BAK activator, to destroy cancer cells more selectively. Our goal is to develop highly effective cancer therapeutics while minimizing side effects from off-target or off-tumor toxicities for the benefit of patients.
